Yes, and my point is that while biopsy only patients were excluded from the trial, there were some number with significant residual tumor who were included, and they outlived their ECA counterparts. Why? Because DCVax works.
So let me get this straight. It is your view that patients with such treatments otherwise go on to live long lives... Hmm... 🧐 Thanks for telling us what little you know.